Many clinical trials are ongoing for a cancer vaccine. For the first time, the “infected cancer vaccine”, worked by two laboratories from Austria and the USA, was administered to humans for testing. Well what does it mean?
Like BionTech, which developed the mRNA vaccine, one of the greatest weapons humanity has against the Covid-19 epidemic. cancer vaccine There are many companies and independent laboratories working on it for many years. Although vaccines that target the disease through mRNA, that is, genetically, take the lead among the vaccines developed against cancer, there is another trump card: Medited smallpox virus.
The modified smallpox virus, which tries to copy itself by entering cancer cells, targets the cancerous area, not the human body. Infected cancer cells burst, thousands of viruses that act as antigens are released and are forced to attack the infected cancerous area. immune system is alarmed.
Smallpox virus modified for vaccine activates human immunity against cancer:
smallpox virus
Vaxinia (CF33-hNIS) The modified smallpox cancer vaccine, named City Of Hope, was developed by the US cancer research center City Of Hope and the Australian-based biotechnology company Imugene. The main target of the vaccine; To stimulate and activate the immune system, which is gradually weakened by cancer. In other words, it is no different from other modified vector vaccines in terms of its working system. However, the most challenging part for the researchers seems to have been the stages where the virus can be modified for the vaccine and have positive results on animals.
Cancer vaccine with virus administered to humans for the first time:
Since it is in the process of a clinical trial, no information is shared about the first volunteer patients to whom the vaccine was administered, but lead researcher and Oncologist at City of Hope Dr. DanengLi, “We believe the vaccine has the potential to improve the situation for our patients. Our previous research; demonstrated that oncological viruses stimulate the immune system to take action against cancer.” made a statement.
To be applied to 100 people with cancer:
with advanced tumors and refused standard treatment methods at least twice In the testing phase focused on patients, the vaccine is expected to be administered to 100 participants. Patients participate voluntarily in the testing phase.
If the initial results are successful, the vaccine will not be released immediately. How it matches the drugs used to treat cancer today will be explored. In addition, evaluations will be made on how much and how much the vaccine shrinks the targeted tumor. For completion of all clinical tests and ancillary studies according to the information disclosed for 2 years there is need.
Source :
https://www.news-medical.net/news/20220518/First-patient-dosed-in-Phase-1-clinical-trial-evaluating-the-safety-of-CF33-hNIS-against-solid-tumors. aspx